OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Andreadis on the Treatment of Relapsed DLBCL

December 4th 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with relapsed diffuse large B-cell lymphoma.

Dr. Pincus on Classifying HER2+ Tumors in Breast Cancer

December 4th 2018

Jenny Pincus, MD, assistant professor of pathology, Northwestern University, Feinberg School of Medicine, discusses the classification of HER2-positive tumors in patients with breast cancer.

Dr. Rule on Treatment of Young, Fit Patients With MCL

December 3rd 2018

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical Center, discusses the treatment of young, fit patients with mantle cell lymphoma.

Dr. Tawbi on Evolving Treatment for Melanoma

December 3rd 2018

Hussein A. Tawbi, MD, PhD, associate professor of medicine, The University of Texas MD Anderson Cancer Center, discusses evolving treatment for patients with melanoma.

Dr. Burtness on the Benefit of Pembrolizumab in Head and Neck Cancer

December 1st 2018

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses the benefit of pembrolizumab (Keytruda) as a treatment for patients with recurrent metastatic head and neck squamous cell carcinoma.

Dr. George on the Use of Adjuvant Sunitinib in RCC

December 1st 2018

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the use of adjuvant sunitinib (Sutent) in the treatment of patients with renal cell carcinoma (RCC).

Dr. Powles on the Current State of Research in Bladder Cancer

December 1st 2018

Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses the current state of research in bladder cancer.

Dr. Hamid on the Inclusion of Patients With Brain Metastases on Melanoma Trials

December 1st 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the inclusion of patients with brain metastases on melanoma clinical trials.

The Sustainability of Rising Drug Prices in Oncology

November 30th 2018

Ryan Bookout, PharmD, president, Hematology/Oncology Pharmacy Association, clinical pharmacist, Moffitt Cancer Center, discusses the sustainability of the field of oncology as drug prices continue to rise.

Dr. Markman on Precision Medicine in Ovarian Cancer

November 30th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the impact of precision medicine in ovarian cancer.

Dr. Makker on Safety Signals With Lenvatinib and Pembrolizumab in Endometrial Cancer

November 30th 2018

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses safety signals with the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) in endometrial cancer.

Dr. Leon Ferre Discusses Ongoing Research in TNBC

November 30th 2018

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses ongoing research in triple-negative breast cancer (TNBC).

Dr. Emberton on the Importance of Multidisciplinary Care in Prostate Cancer

November 30th 2018

Mark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses the importance of a multidisciplinary approach to the treatment of patients with localized prostate cancer.

Dr. O'Connor Discusses Regorafenib Dosing in mCRC

November 30th 2018

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer.

Dr. Triebel on Novel Immunotherapy Combination in Melanoma

November 30th 2018

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immuntep Ltd, discusses a novel immunotherapy combination in melanoma.

Implementing Quality Standards and Personalized Approaches into Oncology

November 30th 2018

Robert D. Orzechowski, MBA, chief operating officer, Lancaster Cancer Center, executive council member, NCODA, discusses the implementation of quality standards and personalized approaches into oncology.

Utility of Genome-Wide Association Studies in Pediatric Oncology

November 29th 2018

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the utility of genome-wide association studies in pediatric oncology.

Dr. Gorantla Addresses Unanswered Questions From the APHINITY Trial

November 29th 2018

Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, addresses the unanswered questions following the APHINITY trial in HER2-positive breast cancer.

Dr. Bradley on Next Steps for Research in Nonmetastatic Prostate Cancer

November 29th 2018

Deborah A. Bradley, MD, oncologist, Levine Cancer Institute, discusses next steps for research in nonmetastatic prostate cancer.

Dr. Kearns on AEs Associated With Surgery in Prostate Cancer

November 29th 2018

James Kearns, MD, assistant professor of medicine, Levine Cancer Institute, discusses adverse events associated with surgery in patients with high-risk prostate cancer.